INTERSTITIAL CYSTITIS TREATMENT PROTOCOLS

间质性膀胱炎治疗方案

• 批准号: 2647416
• 负责人: ALAN J WEIN
• 金额: $ 24.22万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-10 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2647416
• 关键词: antiinflammatory agents; behavior modification; behavioral /social science research tag; biofeedback; clinical research; cooperative study; drug screening /evaluation; heparin; human subject; human therapy evaluation; interstitial cystitis; pentosan; urinary tract disorder chemotherapy

DESCRIPTION: (Abstract of the application) The specific objectives of this proposal are: 1) Study the safety and efficacy of various treatments for Interstitial Cystitis (I.C.); 2) Collect uniform demographic and diagnostic information on patients being evaluated and treated for interstitial Cystitis, before and after therapy; 3) Collect clinical samples (urine, blood), which relate to the specific treatment utilized; 4) Transmit data and send clinical results to a central Data Coordination Center for analysis. The overall goal of this proposal is to conduct double-blind, parallel, randomized controlled clinical trials to determine the safety and efficacy of oral and intravesical therapies for Interstitial Cystitis. L-Arginine orally) and Heparin (intravesically) were selected because they hav been reported as efficacious agents with minimal side effects in the treatment of I.C. symptoms. During phase one we will participate in steering Committee planning and development of study protocols and data instruments. Years two through five we will conduct clinical trials potentially in parallel. In conjunction with Dr. Philip Hanno (Chief of Urology, Division of Urology, Temple University, Philadelphia, PA) and Dr. Kristene Whitmore (Chief of Urology, Allegheny University/ Graduate, Philadelphia, PA), specific objective 2, 3, and 4 have been accomplished as part of our ongoing joint studies on Interstitial Cystitis. The Philadelphia team has demonstrated the ability to work together and form an exceptionally efficient network for I.C. patients across a large geographical area. This group's constant interaction creates a solid professional alignment that benefits patients from near and far.

描述：（应用程序的摘要） 该提案的具体目标是：1）研究安全性和 各种治疗的间隙膀胱炎的功效（I.C.）； 2）收集 评估患者的人口统计和诊断信息均匀 并在治疗前后治疗间质性膀胱炎； 3）收集 临床样品（尿液，血液），与特定治疗有关 利用； 4）传输数据并将临床结果发送到中央数据 分析协调中心。 该提议的总体目标是 进行双盲，平行，随机对照临床试验 确定口服和静脉疗法的安全性和功效 间质性膀胱炎。 L-精氨酸口服）和肝素（插入的）是 之所以选择是因为据报道它们是有效的代理人 I.C.治疗的副作用症状。 在第一阶段，我们将 参加指导委员会计划和研究的发展 协议和数据工具。 第二至五年，我们将进行 临床试验可能并行。 与菲利普博士一起 Hanno（庙宇大学泌尿外科主任，寺庙大学泌尿外科 费城，宾夕法尼亚州）和克里斯妮·惠特莫尔（Kristene Whitmore）博士（阿勒格尼 大学/毕业生，宾夕法尼亚州费城），特定目标2、3和4具有 作为我们正在进行的间隙联合研究的一部分完成 膀胱炎。 费城团队已经证明了工作的能力 共同形成I.C.异常高效的网络患者 跨越大型地理区域。 这个小组的持续互动会创造 一个可靠的专业一致性，使远距离患者受益。